[go: up one dir, main page]

MX2015010769A - Una nueva composicion para esteatosis hepatica no alcoholica (nafld). - Google Patents

Una nueva composicion para esteatosis hepatica no alcoholica (nafld).

Info

Publication number
MX2015010769A
MX2015010769A MX2015010769A MX2015010769A MX2015010769A MX 2015010769 A MX2015010769 A MX 2015010769A MX 2015010769 A MX2015010769 A MX 2015010769A MX 2015010769 A MX2015010769 A MX 2015010769A MX 2015010769 A MX2015010769 A MX 2015010769A
Authority
MX
Mexico
Prior art keywords
fatty liver
nafld
liver disease
nonalcoholic fatty
novel composition
Prior art date
Application number
MX2015010769A
Other languages
English (en)
Other versions
MX346943B (es
Inventor
Pankaj Patel
Jani Rajendrakumar Hariprasad
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2015010769A publication Critical patent/MX2015010769A/es
Publication of MX346943B publication Critical patent/MX346943B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I) o farmacéuticamente aceptable del mismo (sic), en donde 'R' se describe en la presente. Por otra parte, la invención se refiere a una composición que comprende una cantidad terapéuticamente eficaz de un compuesto de fórmula (I) y los métodos para utilizar los compuestos destinados a tratar o prevenir enfermedades como la esteatosis hepática no alcohólica (NAFLD) que incluye hígado graso (esteatosis), esteatohepatitis no alcohólica (NASH) y cirrosis (cicatrización hepática avanzada).
MX2015010769A 2013-04-22 2013-06-25 Una nueva composición para esteatosis hepática no alcohólica (nafld). MX346943B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1468MU2013 IN2013MU01468A (es) 2013-04-22 2013-06-25
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)

Publications (2)

Publication Number Publication Date
MX2015010769A true MX2015010769A (es) 2015-11-26
MX346943B MX346943B (es) 2017-04-06

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010769A MX346943B (es) 2013-04-22 2013-06-25 Una nueva composición para esteatosis hepática no alcohólica (nafld).

Country Status (21)

Country Link
US (3) US20160166539A1 (es)
EP (1) EP2988736A1 (es)
JP (1) JP6246895B2 (es)
KR (1) KR101617812B1 (es)
CN (1) CN105377246B (es)
AP (1) AP2015008674A0 (es)
AU (1) AU2013387996B2 (es)
BR (1) BR112015020600A2 (es)
CA (1) CA2900435C (es)
EA (1) EA201592020A1 (es)
GE (1) GEP201706663B (es)
HK (1) HK1214968A1 (es)
IL (2) IL240183A (es)
IN (1) IN2013MU01468A (es)
MA (1) MA38385A1 (es)
MX (1) MX346943B (es)
MY (1) MY180160A (es)
PH (1) PH12015501795A1 (es)
SG (1) SG11201506218UA (es)
UA (1) UA114360C2 (es)
WO (1) WO2014174524A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2670486T3 (en) 2011-01-31 2016-05-17 Cadila Healthcare Ltd TREATMENT FOR LIPODYSTROPHY
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US10045977B2 (en) * 2016-04-22 2018-08-14 Taiwanj Pharmaceuticals Co., Ltd. Use of nalmefene in non-alcoholic steatohepatitis
EP3551180B1 (en) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
CA3077273A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
WO2020128815A1 (en) 2018-12-18 2020-06-25 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2022128870A1 (en) * 2020-12-18 2022-06-23 Société des Produits Nestlé S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
WO2022246243A1 (en) * 2021-05-21 2022-11-24 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
DE69615016T2 (de) 1995-04-28 2002-05-02 Daiichi Pharmaceutical Co., Ltd. Pentacyclische verbindungen
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IL150821A0 (en) 2000-01-19 2003-02-12 Cadila Healthcare Ltd Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
BRPI0616158A2 (pt) * 2005-09-19 2011-06-07 Johnson & Johnson Pharmaceutical Res & Dev L L C modulação de expressão de receptor de glucagon
KR20090083338A (ko) * 2006-09-18 2009-08-03 알닐람 파마슈티칼스 인코포레이티드 ＳＣＡＰ의 ＲＮＡｉ 조절 및 이들의 치료적 용도
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
BR112012012815B8 (pt) 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
DK2670486T3 (en) 2011-01-31 2016-05-17 Cadila Healthcare Ltd TREATMENT FOR LIPODYSTROPHY
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3039011A1 (en) 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
KR101617812B1 (ko) 2016-05-03
MX346943B (es) 2017-04-06
AU2013387996B2 (en) 2015-12-10
SG11201506218UA (en) 2015-09-29
IL240183A0 (en) 2015-09-24
WO2014174524A8 (en) 2015-10-01
BR112015020600A2 (pt) 2017-07-18
US9814697B2 (en) 2017-11-14
PH12015501795A1 (en) 2015-11-09
CA2900435A1 (en) 2014-10-30
AU2013387996A1 (en) 2015-09-24
HK1214968A1 (zh) 2016-08-12
UA114360C2 (uk) 2017-05-25
EA201592020A1 (ru) 2016-05-31
US20160166539A1 (en) 2016-06-16
KR20150118990A (ko) 2015-10-23
US20170087127A1 (en) 2017-03-30
WO2014174524A1 (en) 2014-10-30
IL247231A (en) 2017-03-30
IL240183A (en) 2016-08-31
JP2016515608A (ja) 2016-05-30
MY180160A (en) 2020-11-23
US20180185330A1 (en) 2018-07-05
GEP201706663B (en) 2017-05-10
CA2900435C (en) 2017-02-14
AP2015008674A0 (en) 2015-08-31
CN105377246A (zh) 2016-03-02
CN105377246B (zh) 2018-03-20
MA38385A1 (fr) 2017-09-29
JP6246895B2 (ja) 2017-12-13
EP2988736A1 (en) 2016-03-02
IN2013MU01468A (es) 2015-04-17

Similar Documents

Publication Publication Date Title
PH12015501795A1 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
MX349159B (es) Derivados deuterados de ivacaftor.
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
NZ726366A (en) Syk inhibitors
MY178621A (en) Deuterated cftr potentiators
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
SG194447A1 (en) Aryl-or heteroaryl-substituted benzene compounds
NZ739248A (en) Inhibitors of hepatitis c virus
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2012012095A (es) Analogos de tiazolidinadiona.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
AR087346A1 (es) Formulaciones de compuestos de tiofeno
EA201291384A1 (ru) Терапевтические агенты 976
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PH12015500353A1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
UA110969C2 (uk) Арил- або гетероарилзаміщені бензольні сполуки та фармацевтична композиція на їх основі
NZ701995A (en) Therapeutic biologic for treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
FG Grant or registration